Former CMS Chief Scully’s Perspective On The Changes In Washington
In a speech before the Food and Drug Law Institute's conference on collaboration between CMS and FDA, Tom Scully, with his usual candor and humor, gave his views on what the outcome of the national elections could mean to the health care industry and on some of the proposals being floated in Washington. Below are some excerpts from his presentation on Nov. 18 in Washington, D.C. Scully served as CMS administrator from 2001 to 2003. He currently divides his time between the law firm Alston & Bird, where he is senior counsel, and the private equity firm Welsh, Carson, Anderson & Stowe, where he is a general partner.
You may also be interested in...
Some Medicare Part D experts are warning of the unintended consequences that could result from applying Medicaid drug pricing policy to low-income seniors enrolled in Medicare Part D drug plans
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.